Sarepta Therapeutics Announces Second Quarter 2018 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Sarepta Therapeutics (SRPT) Gains 8.5% Off the Open
August 9, 2018 9:40 AM EDTSarepta Therapeutics (NASDAQ: SRPT) gains 8.5% off the open following results, update.
... MoreBaird Reiterates Outperform on Sarepta Therapeutics (SRPT)
August 9, 2018 9:06 AM EDTBaird reiterated an Outperform rating and $202.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) following a quarterly update. Exondys51 sales come in ahead of expectations at $73.5M vs. consensus estimate of $71.0M, a $8.9 sequential increase over 1Q18. Sales continue to track towards the... More
Sarepta Therapeutics (SRPT) Posts Smaller Q2 Loss on Higher Revenues
August 8, 2018 4:21 PM EDTSarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.43), $0.46 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $73.5 million versus the consensus estimate of $71.59 million.
We are very pleased to report another strong quarter, marrying our vision to become one of the most meaningful precision genetic medicine companies globally with a strong focus on execution against both our near- and long-term range goals, stated Doug Ingram, Sareptas president and chief... More
